Patents by Inventor Stephan GASSER

Stephan GASSER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
    Publication number: 20240100063
    Abstract: The present invention relates to combination therapies employing PD-1 axis binding antagonists and LRRK2 inhibitors and, and the use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: April 20, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Denise Corti, Stephan Gasser, Gabor Gyulveszi, Claudio Murgia, Tobias Schmidt, Martha Liliana Serrano Serrano, Pablo Umaña
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS
    Publication number: 20230227917
    Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determing the abundance of stem cell maintenance-related genes in a tumor tissue sample. The abundance of stem cell maintenance-related genes characterized by enhanced expressions of ASPM, CNOT3, LRPS and PBX1 predicts clinical response to the PD-L1 blockade treatment.
    Type: Application
    Filed: May 4, 2021
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan Gasser, Andreas Roller
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 11608376
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
  • AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2
    Publication number: 20220017637
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: June 22, 2021
    Publication date: January 20, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Thomas HOFER, Teemu Tapani JUNTTILA, Christian KLEIN, Christine KUETTEL, Jenny Tosca THOM, Pablo UMAÑA
  • TUMOR-TARGETED SUPERAGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20200223925
    Abstract: The present invention relates to tumor targeted superagonistic antigen binding molecules capable of multivalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Jenny Tosca THOM, Pablo UMAÑA
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20200199234
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Power tool
    Patent number: 9004191
    Abstract: The invention relates to a power tool, such as an impact drilling machine, impact screwdriver, saber saws, grinders, or the like, comprising a housing. In the housing, an electric motor and an electric or electronic module that is attached to holders in the housing, for example, an electric switch or electronics, are provided. Between the holders in the housing and the electrical or electronic modules, a vibration decoupling element is disposed.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: April 14, 2015
    Assignee: Marquardt GmbH
    Inventors: Jens Müller, Stephan Gasser
  • POWER TOOL
    Publication number: 20100314147
    Abstract: The invention relates to a power tool, such as an impact drilling machine, impact screwdriver, saber saws, grinders, or the like, comprising a housing. In the housing, an electric motor and an electric or electronic module that is attached to holders in the housing, for example, an electric switch or electronics, are provided. Between the holders in the housing and the electrical or electronic modules, a vibration decoupling element is disposed.
    Type: Application
    Filed: July 9, 2010
    Publication date: December 16, 2010
    Applicant: Marquardt GmbH
    Inventors: Jens MÜLLER, Stephan GASSER